What question did this study set out to answer?

To determine the prevalence, clinical characteristics, and evolution of anti-erythropoietin antibody-associated pure red-cell aplasia among chronic dialysis patients in Switzerland.

July 13, 2004Nephrology Dialysis TransplantationOpen Access

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases

View Full Paper

Ask AI

Bookmark

Authors

CSCarlo SchönholzerAstellas Pharma (Japan)GKG KeuschPHV Dialysezentrum LNL. NiggUniversity Hospital of Zurich

Discussion

Member takes

Implication

Nationwide survey reveals high rates of anti-erythropoietin-associated pure red-cell aplasia in hemodialysis patients, highlighting risks linked to subcutaneous formulation exposure.

Key Points

To determine the prevalence, clinical characteristics, and evolution of anti-erythropoietin antibody-associated pure red-cell aplasia among chronic dialysis patients in Switzerland.
Conducted a survey across all 69 dialysis units in Switzerland in January 2003 on behalf of the Swiss Society of Nephrology.
Gathered and analyzed clinical and biological data on suspected cases, verifying findings against health authority and pharmaceutical company databases.
Identified five confirmed cases of pure red-cell aplasia with neutralizing anti-erythropoietin antibodies among approximately 2,300 treated patients (exposure of 9,900 patient-years over 4.3 years).
All five patients received subcutaneous erythropoietin via hemodialysis (two epoetin-alpha, one epoetin-beta, two both) and developed refractory anemia at a median of 10 months (range: 7–54 months).

Cite This Study

Schönholzer et al. (2004) studied this question.

synapsesocial.com/papers/6a9fc1833ce5f043f590db82 https://doi.org/10.1093/ndt/gfh307

View Full Paper

Ask AI

Bookmark

Implication

Nationwide survey reveals high rates of anti-erythropoietin-associated pure red-cell aplasia in hemodialysis patients, highlighting risks linked to subcutaneous formulation exposure.

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases

Discussion

Member takes

Implication

Key Points

Cite This Study

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider